MedTrace Logo

Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure

NCT04394754 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2023-05-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of three novel digital health technologies versus usual care in the management of congestive heart failure, as assessed by a primary outcome of improvement in quality of life, and a variety of secondary outcomes that include metrics measuring patient and provider satisfaction, clinical efficiency, and patient outcomes.

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

BodyPort

Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.

OTHER

Noom

Patients will receive a subscription to use Noom, a personalized diet and weight management application.

OTHER

Conversa

patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.

Sponsors & Collaborators

Principal Investigators

  • Francis P Wilson, MD MSCE · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-21
Primary Completion
2021-09-20
Completion
2021-12-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04394754 on ClinicalTrials.gov